Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Dow Jones Dives 450 Points On Moody's Bank Downgrades; Palantir Plunges On Earnings

The Dow Jones Industrial Average dived 450 points Tuesday on Moody's bank downgrades. Hot AI stock Palantir Technologies dived on second-quarter earnings results.

Investors Business Daily

Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

WEKU

AI Stock Marvell And Eli Lilly Lead 5 Names Near Buy Points As S&P 500 Rallies On

Top AI stock Marvell Technology and Eli Lilly lead this weekend's watch list of five stocks near buy points as the new S&P 500 bull market revs back up.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates

Biogen stock dropped Tuesday after the biotechnology firm said it's eliminating 1,000 jobs as part of a strategy to cut operating expenses.

Investors Business Daily

The obesity epidemic is fuelled by biology, not lack of willpower

Since the time a human first used a tool to make life easier, increased weight has been inevitable.

The Conversation

IBD Stock Of The Day Novo Nordisk, A Weight-Loss Kingpin, Just Retook Its 50-Day Line

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

Investors Business Daily

Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?

Trial results of a new drug to treat Alzheimer’s disease, donanemab, shows it can slow cognitive decline by 35%. The drug has been hailed as a “turning point” in Alzheimer’s treatment.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Futures Rise After Market Rallies On Microsoft AI Push; Netflix, Tesla Earnings On Tap

Microsoft AI pricing fueled the Nasdaq, which is increasingly extended. Netflix and Tesla earnings loom.

Investors Business Daily

Microsoft, Eli Lilly Bolster Stock Market Upside; This Sector Is Smashing The Dow Jones Industrial Average's Performance

ARCB also is trying to storm past a cup with handle that shows a 101.49 buy point.

Investors Business Daily

IBD Stock Of The Day Eli Lilly: How Alzheimer's And Weight Loss Are Driving A New Breakout

Eli Lilly stock is Tuesday's IBD Stock Of The Day. Shares are rising as Lilly's Alzheimer's treatment appears "very competitive" with Biogen's.

Investors Business Daily

Should Investors Start Watching Eli Lilly & Co. (LLY) This Week?

Despite macroeconomic headwinds dampening the growth of various industries, Eli Lilly and Company (LLY) has remained resilient and is ramping up investments in medical research. So, will it be a good watchlist addition this week? Keep reading.

StockNews.com

New drug found to slow Alzheimer’s hailed as turning point

Donanemab has been found to slow down the disease in a clinical trial.

The Independent UK

Everything we know about breakthrough Alzheimer’s drug Donanemab

Alzheimer’s disease is the most common cause of dementia in the UK

The Independent UK

Alzheimer’s: ‘Turning point’ in fight against disease as drug found to slow decline by up to 35%

Experts say ‘we’re entering a new era where Alzheimer’s disease could become treatable’

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Experts urge health regulators to approve ‘turning point’ dementia drugs

Exclusive: As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial

The Guardian - UK

What impact will Alzheimer’s drug donanemab have?

While it is not a cure, proof that drugs can alter course of disease is regarded as significant triumph

Investors Business Daily

How Weight-Loss Behemoth Lilly Is Trying To Leapfrog Chief Rival Novo

Eli Lilly stock jumped Friday after unveiling a nearly $2 billion takeover that could bolster its efforts among weight-loss drugs.

Investors Business Daily

S&P 500, Nasdaq Hit Fresh 52-Week Highs As Inflation Fears Ebb; Salesforce, Delta, JPMorgan In Focus: Weekly Review

The S&P 500 and Nasdaq led a strong market rally this week as inflation fears wane. Salesforce, Delta Air Lines, JPMorgan were key newsmakers

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

Investors Business Daily

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

Fortune

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

The Guardian - UK

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

The Guardian - UK

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

Zenger

FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

Investors Business Daily

Stock Market Rebounds Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review

The market rally had a strong week, with the major indexes rebounding toward 2023 highs and many stocks flashing buy signals.

1 … 19 20 21 22

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations